European Commission grants approval to the first Tocilizumab biosimilar

Written By : Isra Zaman

Medically Reviewed By : Dr. Kamal Kant Kohli

Published On 2023-09-23 04:30 GMT | Update On 2023-09-23 09:18 GMT

The European Commission has granted marketing authorization to Fresenius Kabi for its tocilizumab biosimilar, Tyenne. This marks the first approval of a tocilizumab biosimilar in Europe, as announced in a press release on September 19 by the manufacturer, Fresenius Kabi. Tyenne is indicated for treating various conditions, including rheumatoid arthritis, systemic juvenile idiopathic arthritis, juvenile idiopathic polyarthritis, giant cell arteritis, CAR-T cell-induced severe or life-threatening cytokine release syndrome and COVID-19.

The European Medicines Agency opinion letter has confirmed that Tyenne demonstrates "comparable quality, safety, and efficacy" to the reference product RoActemra (tocilizumab), an interleukin-6 receptor inhibitor that gained initial authorization in the European Union back in 2009. Tyenne will be available in two forms: a 162 mg/mL prefilled syringe for subcutaneous injection and a 20 mg/mL concentrate for a solution suitable for intravenous administration.

Company’s CEO Pierluigi Antonelli said, “Being on the cutting edge of proposing an affordable, high-quality, and safe tocilizumab treatment option to health care providers and patients living with autoimmune diseases is an exciting step in our mission to provide access to alternative treatment options.

Full View

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Isra Zaman

Isra Zaman is a Life Science graduate from Daulat Ram College, Delhi University, and a postgraduate in Biotechnology from Amity University. She has a flair for writing, and her roles at Medicaldialogues include that of a Sr. content writer and a medical correspondent. Her news pieces cover recent discoveries and updates from the health and medicine sector. She can be reached at editorial@medicaldialogues.in.

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

European Commission grants approval to the first Tocilizumab biosimilar

Similar News

WHO Updates Essential Medicines List, Adds Cancer, Diabetes and Obesity Drugs

Common Nasal Spray Cuts COVID Risk by Two-Thirds in Clinical Trial

Glipizide and Metformin FDC - Effective, Safe and Cost-Effective in T2D: Latest Indian Real-World Study

Study Reveals Potassium-Rich Foods May Lower Irregular Heartbeat Risk

Study Reveals Daily Intake of Five Mushrooms May Reduce Alzheimer's and Heart Disease Risk

Managing Nasal Congestion in Allergic Rhinitis: Whats the Mechanism of Action of Allegra D ?

The Prediabetes Show, Episode 4: Metformin in Prediabetes - A Vaccination Pill for Diabetes Prevention in 65 Countries

WHO-Endorsed Mosquito Repellent Cuts Malaria Risk by Over 50 Percent: Study Finds